Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation.

Kirkton RD, Santiago-Maysonet M, Lawson JH, Tente WE, Dahl SLM, Niklason LE, Prichard HL.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau6934. doi: 10.1126/scitranslmed.aau6934.

PMID:
30918113
2.

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.

Bylsma LC, Reichert H, Gage SM, Roy-Chaudhury P, Nordyke RJ, Fryzek J, Dahl SLM, Lithgow T, Lawson JH.

Am J Nephrol. 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24.

PMID:
30677763
3.

Lipocalin-2 Functions as Inhibitor of Innate Resistance to Mycobacterium tuberculosis.

Dahl SL, Woodworth JS, Lerche CJ, Cramer EP, Nielsen PR, Moser C, Thomsen AR, Borregaard N, Cowland JB.

Front Immunol. 2018 Nov 26;9:2717. doi: 10.3389/fimmu.2018.02717. eCollection 2018.

4.

Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype.

Imeri F, Nolan KA, Bapst AM, Santambrogio S, Abreu-Rodríguez I, Spielmann P, Pfundstein S, Libertini S, Crowther L, Orlando IMC, Dahl SL, Keodara A, Kuo W, Kurtcuoglu V, Scholz CC, Qi W, Hummler E, Hoogewijs D, Wenger RH.

Kidney Int. 2019 Feb;95(2):375-387. doi: 10.1016/j.kint.2018.08.043. Epub 2018 Nov 27.

PMID:
30502050
5.

Interaction of antivirals with a heptameric bundle model of the p7 protein of hepatitis C virus.

Dahl SL, Kalita MM, Fischer WB.

Chem Biol Drug Des. 2018 Apr;91(4):942-950. doi: 10.1111/cbdd.13162. Epub 2018 Jan 23.

PMID:
29251816
6.

Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection.

Kirkton RD, Prichard HL, Santiago-Maysonet M, Niklason LE, Lawson JH, Dahl SLM.

J Surg Res. 2018 Jan;221:143-151. doi: 10.1016/j.jss.2017.08.035. Epub 2017 Sep 19.

7.

Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes.

Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH.

Eur J Vasc Endovasc Surg. 2017 Oct;54(4):513-522. doi: 10.1016/j.ejvs.2017.06.024. Epub 2017 Aug 23. Review.

8.

Lipocalin-2 from both myeloid cells and the epithelium combats Klebsiella pneumoniae lung infection in mice.

Cramer EP, Dahl SL, Rozell B, Knudsen KJ, Thomsen K, Moser C, Cowland JB, Borregaard N.

Blood. 2017 May 18;129(20):2813-2817. doi: 10.1182/blood-2016-11-753434. Epub 2017 Apr 10. No abstract available.

9.

ELM 2016--data update and new functionality of the eukaryotic linear motif resource.

Dinkel H, Van Roey K, Michael S, Kumar M, Uyar B, Altenberg B, Milchevskaya V, Schneider M, Kühn H, Behrendt A, Dahl SL, Damerell V, Diebel S, Kalman S, Klein S, Knudsen AC, Mäder C, Merrill S, Staudt A, Thiel V, Welti L, Davey NE, Diella F, Gibson TJ.

Nucleic Acids Res. 2016 Jan 4;44(D1):D294-300. doi: 10.1093/nar/gkv1291. Epub 2015 Nov 28.

10.

Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses.

Sørensen OE, Clemmensen SN, Dahl SL, Østergaard O, Heegaard NH, Glenthøj A, Nielsen FC, Borregaard N.

J Clin Invest. 2014 Oct;124(10):4539-48. doi: 10.1172/JCI76009. Epub 2014 Sep 17.

11.

What is the greatest regulatory challenge in the translation of biomaterials to the clinic?

Prestwich GD, Bhatia S, Breuer CK, Dahl SL, Mason C, McFarland R, McQuillan DJ, Sackner-Bernstein J, Schox J, Tente WE, Trounson A.

Sci Transl Med. 2012 Nov 14;4(160):160cm14. doi: 10.1126/scitranslmed.3004915.

PMID:
23152323
12.

Bioengineered vascular grafts: can we make them off-the-shelf?

Dahl SL, Blum JL, Niklason LE.

Trends Cardiovasc Med. 2011 Apr;21(3):83-9. doi: 10.1016/j.tcm.2012.03.004. Review.

PMID:
22626247
13.

An early study on the mechanisms that allow tissue-engineered vascular grafts to resist intimal hyperplasia.

Prichard HL, Manson RJ, DiBernardo L, Niklason LE, Lawson JH, Dahl SL.

J Cardiovasc Transl Res. 2011 Oct;4(5):674-82. doi: 10.1007/s12265-011-9306-y. Epub 2011 Jul 12.

14.

Readily available tissue-engineered vascular grafts.

Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, Manson RJ, Tente WE, DiBernardo L, Hensley MT, Carter R, Williams TP, Prichard HL, Dey MS, Begelman KG, Niklason LE.

Sci Transl Med. 2011 Feb 2;3(68):68ra9. doi: 10.1126/scitranslmed.3001426.

15.

Effects of mechanical stretch on collagen and cross-linking in engineered blood vessels.

Solan A, Dahl SL, Niklason LE.

Cell Transplant. 2009;18(8):915-21. doi: 10.3727/096368909X471161. Epub 2009 Apr 9.

16.

A microstructurally motivated model of the mechanical behavior of tissue engineered blood vessels.

Dahl SL, Vaughn ME, Hu JJ, Driessen NJ, Baaijens FP, Humphrey JD, Niklason LE.

Ann Biomed Eng. 2008 Nov;36(11):1782-92. doi: 10.1007/s10439-008-9554-4. Epub 2008 Aug 22.

17.

An ultrastructural analysis of collagen in tissue engineered arteries.

Dahl SL, Vaughn ME, Niklason LE.

Ann Biomed Eng. 2007 Oct;35(10):1749-55. Epub 2007 Jun 14.

18.

Mechanical properties and compositions of tissue engineered and native arteries.

Dahl SL, Rhim C, Song YC, Niklason LE.

Ann Biomed Eng. 2007 Mar;35(3):348-55. Epub 2007 Jan 6.

19.

Feasibility of vitrification as a storage method for tissue-engineered blood vessels.

Dahl SL, Chen Z, Solan AK, Brockbank KG, Niklason LE, Song YC.

Tissue Eng. 2006 Feb;12(2):291-300.

PMID:
16548687
20.

Effects of copper and cross-linking on the extracellular matrix of tissue-engineered arteries.

Dahl SL, Rucker RB, Niklason LE.

Cell Transplant. 2005;14(10):861-8.

PMID:
16454361
21.

Effects of copper and cross-linking on the extracellular matrix of tissue-engineered arteries.

Dahl SL, Rucker RB, Niklason LE.

Cell Transplant. 2005;14(6):367-74. Corrected and republished in: Cell Transplant. 2005;14(10):861-8.

PMID:
16180655
22.

Blood vessels engineered from human cells.

Poh M, Boyer M, Solan A, Dahl SL, Pedrotty D, Banik SS, McKee JA, Klinger RY, Counter CM, Niklason LE.

Lancet. 2005 Jun 18-24;365(9477):2122-4.

PMID:
15964449
23.

Decellularized native and engineered arterial scaffolds for transplantation.

Dahl SL, Koh J, Prabhakar V, Niklason LE.

Cell Transplant. 2003;12(6):659-66.

PMID:
14579934
24.

Decellularized Native and Engineered Arterial Scaffolds for Transplantation.

Dahl SLM, Koh J, Prabhakar V, Niklason LE.

Cell Transplant. 2003 Sep;12(6):659-666. doi: 10.3727/000000003108747136.

PMID:
28866947
25.

Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.

Murray KM, Dahl SL.

Ann Pharmacother. 1997 Nov;31(11):1335-8. Review.

PMID:
9391689
26.

Advances and issues in the pharmacotherapy of rheumatoid arthritis.

Dahl SL.

J Clin Pharm Ther. 1995 Jun;20(3):131-47. Review.

PMID:
7593375
27.

Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.

Dahl SL.

Ann Pharmacother. 1993 Apr;27(4):456-63. Review.

PMID:
8477124
28.
29.

Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials.

Dahl SL, Samuelson CO, Williams HJ, Ward JR, Karg M.

Pharmacotherapy. 1990;10(2):79-84.

PMID:
2112243
30.

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.

Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, Weisman MH, Schlegel S, Michaels RM, Luggen ME, et al.

Arthritis Rheum. 1988 Jun;31(6):702-13.

PMID:
2898244
31.

One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo.

Williams HJ, Dahl SL, Ward JR, Karg M, Willkens RF, Meenan RF, Altz-Smith M, Clegg DO, Mikkelsen WM, Kay DR, et al.

Arthritis Rheum. 1988 Jan;31(1):9-14.

PMID:
3125841
32.

The effect of cimetidine on serum concentrations of piroxicam.

Mailhot C, Dahl SL, Ward JR.

Pharmacotherapy. 1986 May-Jun;6(3):112-7.

PMID:
3488542
33.

Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate.

Dahl SL, Coleman ML, Williams HJ, Altz-Smith M, Kay DR, Paulus HE, Weinstein A, Kaplan S.

Arthritis Rheum. 1985 Nov;28(11):1211-8.

PMID:
3933523
34.

Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis.

Williams HJ, Furst DE, Dahl SL, Steen VD, Marks C, Alpert EJ, Henderson AM, Samuelson CO Jr, Dreyfus JN, Weinstein A, et al.

Arthritis Rheum. 1985 Mar;28(3):308-14.

PMID:
3884019
35.
36.
37.

Update on drug therapy. IV. Parenteral cephalosporins.

Dahl SL, Elenbaas J, Hamburger S.

J Am Med Womens Assoc (1972). 1980 Apr;35(4):99-100, 107-8. Review. No abstract available.

PMID:
6246160

Supplemental Content

Support Center